At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 698 enrolled
Drug / intervention
mRNA-1011.1 +5 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age
In Brief
A Phase 2 clinical trial evaluating mRNA-1011.1, mRNA-1011.2, and 4 other interventions for Seasonal Influenza. Completed, enrolled 698 participants across 22 sites.
Detailed Summary
The purpose of this study is to measure the safety and the immune response to 3 next-generation influenza vaccine candidates (mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1) compared with influenza vaccine candidate mRNA-1010 controls in healthy adult participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSeasonal Influenza
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202420252026
Enrollment StartMar 2023
First PostedApr 2023
Primary CompletionNov 2023
TodayJul 2026
First PostedApr 24, 2023
Enrollment StartMar 27, 2023
Primary CompletionNov 20, 2023
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 3.2 years ago
Interventions
mRNA-1011.1biological
Sterile liquid for injection
mRNA-1011.2biological
Sterile liquid for injection
mRNA-1012.1biological
Sterile liquid for injection
mRNA-1010biological
Sterile liquid for injection
mRNA-1010.2biological
Sterile liquid for injection
mRNA-1010.3biological
Sterile liquid for injection